Accueil   Diary - News   All news Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®

Scancell and ImmunID announce collaboration to predict SCIB1 responders using ImmunTraCkeR®

ImmunID nouveau logo
Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, and ImmunID, an immune molecular diagnostics company, today announce an agreement to collaborate on a research project aimed at predicting which patients will respond best to SCIB1 treatment. The study will use ImmunID’s flagship clinical product, ImmunTraCkeR®, before and during treatment, to assess the immune-modulatory effect of Scancell’s SCIB1 ImmunoBody® vaccine in patients with Stage III/IV metastatic melanoma.

Read the press release